The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin
Open accessAbstract
Purpose: On initial publication of GI Intergroup Radiation Therapy Oncology Group (RTOG) 98-11 [A Phase III Randomized Study of 5-Fluorouracil (5-FU), Mitomycin, and Radiotherapy Versus 5-Fluorouracil, Cisplatin and Radiotherapy in Carcinoma of the Anal Canal], concurrent chemoradiation (CCR) with fluorouracil (FU) plus mitomycin (MMC) decreased colostomy failure (CF) when compared with induction plus concurrent FU plus cisplatin (CDDP), but did not significantly impact disease-free survival (DFS) or overall survival (OS) for anal canal carcinoma. The intent of the updated analysis was to determine the long-term impact of treatment on survival (DFS, OS, colostomy-free survival [CFS]), CF, and relapse (locoregional failure [LRF], distant metastasis) in this patient group. Patients and Methods: Stratification factors included sex, clinical node status, and primary size. DFS and OS were estimated univariately by the Kaplan-Meier method, and treatment arms were compared by log-rank test. Time to relapse and CF were estimated by the cumulative incidence method and treatment arms were compared by using Gray's test. Multivariate analyses used Cox proportional hazard models to test for treatment differences after adjusting for stratification factors. Results: Of 682 patients accrued, 649 were analyzable for outcomes. DFS and OS were statistically better for RT + FU/MMC versus RT + FU/CDDP (5-year DFS, 67.8% v 57.8%; P = .006; 5-year OS, 78.3% v 70.7%; P = .026). There was a trend toward statistical significance for CFS (P = .05), LRF (P = .087), and CF (P = .074). Multivariate analysis was statistically significant for treatment and clinical node status for both DFS and OS, for tumor diameter for DFS, and for sex for OS. Conclusion: CCR with FU/MMC has a statistically significant, clinically meaningful impact on DFS and OS versus induction plus concurrent FU/CDDP, and it has borderline significance for CFS, CF, and LRF. Therefore, RT + FU/MMC remains the preferred standard of care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Bartelink, H., Roelofsen, F., Eschwege, F., Rougier, P., Bosset, J. F., Gonzalez, D. G., Peiffert, D., van Glabbeke, M., & Pierart, M. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.2040 · Cited by 1,319
Flam, M. S., John, M., Pajak, T. F., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2527 · Cited by 1,095
Ajani, J. A. (2008) · JAMA · doi:10.1001/jama.299.16.1914 · Cited by 837
Self-citationRepopulation of cancer cells during therapy: an important cause of treatment failure
Kim, J. J., & Tannock, I. F. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1650 · Cited by 686
Kachnic, L. A., Winter, K., Myerson, R. J., Goodyear, M. D., Willins, J., Esthappan, J., Haddock, M. G., Rotman, M., Parikh, P. J., Safran, H., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.09.023 · Cited by 621
Self-citationThe randomization and stratification of patients to clinical trials
Zelen, M. (1974) · Journal of Chronic Diseases · doi:10.1016/0021-9681(74)90015-0 · Cited by 613
The effect of treatment duration in the local control of cervix cancer
Fyles, A., Keane, T. J., Barton, M., & Simm, J. (1992) · Radiotherapy and Oncology · doi:10.1016/0167-8140(92)90247-r · Cited by 389
Dose fractionation and tumour repopulation in radiotherapy for bladder cancer
Maciejewski, B., & Majewski, S. (1991) · Radiotherapy and Oncology · doi:10.1016/0167-8140(91)90033-d · Cited by 166
Low dose hyper-radiosensitivity and increased radioresistance in mammalian cells
B. MARPLES, P. L. (1997) · International Journal of Radiation Biology · doi:10.1080/095530097143725 · Cited by 145
Repopulation in radiation oncology: perspectives of clinical research
Bentzen, S. M. (2003) · International Journal of Radiation Biology · doi:10.1080/09553000310001597002 · Cited by 63
Neoadjuvant Cisplatin Chemotherapy Before Chemoradiation: A Flawed Paradigm?
Glynne‐Jones, R., & Hoskin, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3133 · Cited by 63
Ajani, J. A., Wang, X., Izzo, J. G., Crane, C. H., Eng, C., Skibber, J. M., Das, P., & Rashid, A. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0812-6 · Cited by 59
Self-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2014.07.030 · Cited by 481
Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu159 · Cited by 355
Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up
Glynne-Jones, R., Nilsson, P. J., Aschele, C., Goh, V., Peiffert, D., Cervantes, A., & Arnold, D. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2014.04.013 · Cited by 269
Metadata
- Authors
- Gunderson, L. L., Winter, K. A., Ajani, J. A., Pedersen, J. E., Moughan, J., Benson, A. B., Thomas, C. R., Mayer, R. J., Haddock, M. G., Rich, T. A., & Willett, C. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-12-10
- Volume
- 30
- Issue
- 35
- Pages
- 4344-4351
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2158244375
- Cited by
- 588
- References
- 21
- FWCI
- 34.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.